The intravitreal injection (IVT) of anti-vascular endothelial growth factor (anti-VEGF) therapy has become the standard care for retinal vascular diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema, and retinal vein occlusion (RVO) [1]. Here, VEGFA is linked to wet macular degeneration.